Recent Updates
Recently added Catalysts
RLAY

Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights

Thursday, October 27, 2022 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 20
Price reaction · baseline $22 (2022-10-26 close) · hit after-hours · clean, no other RLAY news in the window
day 0 close
-1.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+284%
120-day peak, hindsight
Typical move
11.8%
average across 6 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
RLY-8161
Phase 1 · Advanced NRAS-Mutant Melanoma

Full Press Release Details

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2022 financial results and corporate highlights after the close of market on Thursday, November 3, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release.
About Relay Therapeutics
ShareAdd on Google
Tags: RLAY Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 27, 2022

Biotech snapshot

Cash runway
$911M liquidity · $18M/mo burn
~50 mo
Minimal dilution risk
Lead asset
RLY-8161Phase 1
Advanced NRAS-Mutant Melanoma →

Catalyst track record

+284%
best trade around RLAY's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RLAY.

See every catalyst's timing & PoA →